Table 1. Hub cell proliferation after EGFR pathway activation.
| Gal4 driver | UAS line (BDSC #) | Days at 31 °C | % Testes with PH3-positive hub cells |
|---|---|---|---|
| Controls | |||
| E132-Gal4, Gal80ts | UAS-Rbf-RNAi (41863) | 7 | 31% (n = 34/108)**** |
| UAS-Rbf-RNAi (36744) | 7 | 29% (n = 53/183)**** | |
| UAS-GFP-RNAi (9330 or 9331) | 7 | 0% (n = 0/237) | |
| C587-Gal4, Gal80ts | UAS-GFP-RNAi (9331) | 7 | 0% (n = 0/294) |
| Downstream Effectors and Transcription Factors | |||
| E132-Gal4, Gal80ts | UAS-Pointed.P1 (869) | 7 | 7% (n = 4/55)** |
| UAS-Pointed.P2 (399) | 7 | 6% (n = 6/100)*** | |
| UAS-Ras85D.V12 (4847) | 3 | 11% (n = 2/18)** | |
| 5 | 6% (n = 2/36)* | ||
| UAS-Rolled (59006) | 7 | 0% (n = 0/92)ns | |
| Receptors | |||
| E132-Gal4, Gal80ts | UAS-Egfr Type I (9534) | 7 | 1% (n = 1/143)ns |
| UAS-Egfr Type II (9533) | 7 | 4% (n = 5/117)** | |
| UAS-Egfr λ (59843) | 7 | < 1% (n = 1/163)ns | |
| UAS-PvR λ (58496) | 7 | 1% (n = 1/106)ns | |
| UAS-PvR λ (58428) | 7 | 0% (n = 0/156)ns | |
| UAS-InR (8250) | 7 | 0% (n = 0/48)ns | |
| UAS-InR (8263) | 7 | 0% (n = 0/41)ns | |
| UAS-Heartless λ (5367) | 7 | 2% (n = 3/181)ns | |
| UAS-Breathless λ (29045) | 7 | 0% (n = 0/90)ns | |
| Negative Regulators | |||
| E132-Gal4, Gal80ts | UAS-Sprouty-RNAi (36709) | 7 | 3% (n = 4/144)* |
| UAS-Pten-RNAi (33643) | 7 | 3% (n = 4/125)* | |
| UAS-Argos-RNAi (28383) | 7–8 | < 1% (n = 1/170)ns | |
| C587-Gal4, Gal80ts | UAS-Argos-RNAi (28383) | 7–8 | 2% (n = 6/348)* |
Percentages in bold are significant compared to the negative control (UAS-GFP-RNAi driven by the same Gal4 driver).
Fisher’s Exact Test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns = not significant.